An Exploration of the Effect of Modafinil on Olanzapine Associated Weight Gain in Normal Human Subjects

Biological Psychiatry

Volumn 65, Issue 7, 2009, Pages 607-613

  Roerig, James L ^a,b   Steffen, Kristine J ^a,b   Mitchell, James E ^a,b   Crosby, Ross D ^a,b   Gosnell, Blake A ^c  

^a UND School of Medicine & Health Sciences Southeast Campus   (United States)

^b NEUROPSYCHIATRIC RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Feeding laboratory; modafinil; normal control subjects; obesity; olanzapine; weight gain

Indexed keywords

MODAFINIL; OLANZAPINE; PLACEBO;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APPETITE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BEDTIME DOSAGE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EPWORTH SLEEPINESS SCALE; FEEDING BEHAVIOR; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MORNING DOSAGE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; TREMOR; WEIGHT GAIN; XEROSTOMIA;

ADULT; ANTIPSYCHOTIC AGENTS; BENZHYDRYL COMPOUNDS; BENZODIAZEPINES; BODY MASS INDEX; CENTRAL NERVOUS SYSTEM STIMULANTS; FEMALE; HUMANS; MALE; WEIGHT GAIN;

EID: 61549102473     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2008.10.037     Document Type: Article

References (50)

1. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al., Clinical antipsychotic trials of intervention effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 (2005) 1209-1223
2. Casey D.E. Implications of the CATIE trial on treatment: Extrapyramidal symptoms. CNS Spectr 11 7 suppl 7 (2006) 25-31
3. Green A.I., Lieberman J.A., Hamer R.M., Glick I.D., Gur R.E., Kahn R.S., et al. Olanzapine and haloperidol in first episode psychosis: Two-year data. Schizophr Res 86 (2006) 234-243
4. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156 (1999) 1686-1696
5. Wirshing D.A., Spellberg B.J., Erhart S.M., Marder S.R., and Wirshing W.C. Novel antipsychotics and new onset diabetes. Biol Psychiatry 4 (1998) 778-783
6. Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain: A literature analysis. Drug Saf 29 (2006) 303-319
7. Fakhouri W. Extent of distress caused by adverse experiences associated with antipsychotic treatment. Eur Neuropsychopharmacol 9 suppl 5 (1999) S285
8. Sachs G.S., and Guille C. Weight gain associated with use of psychotropic medications. J Clin Psychiatry 60 suppl 21 (1999) 16-19
9. Kawachi I. Physical and psychological consequences of weight gain. J Clin Psychiatry 60 suppl 21 (1999) 5-9
10. Roerig J.L., Mitchell J.E., de Zwaan M., Crosby R.D., Gosnell B.A., Steffen K.J., et al. A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviors. J Clin Psychopharmacol 25 (2005) 413-418
11. Peuskens J., and Link C.G. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 96 (1997) 265-273
12. McIntyre R.S., Mancini D.A., and Basile V.S. Mechanisms of antipsychotic-induced weight gain. J Clin Psychiatry 62 suppl 23 (2001) 23-29
13. Theisen F.M., Haberhausen M., Firnges M.A., Fleischhaker C., Clement H.W., Heinzel-Gutenbrunner M., et al. No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J 7 (2007) 275-281
14. Kroeze W.K., Hufeisen S.J., Popadak B.A., Renock S.M., Steinberg S., Ernsberger P., et al. H 1 - histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28 (2003) 519-526
15. Matsui-Sakata A., Ohtani H., and Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 20 (2005) 368-378
16. Kim S.F., Huang A.S., Snowman A.M., Teuscher C., and Snyder S.H. Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A 104 (2007) 3456-3459
17. Minzenberg M.J., and Carter C.S. Modafinil: A review of neurochemical actions and effects on cognition. Neuropsychopharmacology 33 (2007) 1477-1502
18. Ishizuka T., Sakamoto Y., Sakurai T., and Yamatodani A. Modafinil increases histamine release in the anterior hypothalamus of rats. Neurosci Lett 339 (2003) 143-146
19. Bastuji H., and Jouvet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuropsychopharmacol Biol Psychiatry 12 (1988) 695-700
20. Touret M., Sallanon-Moulin M., and Jouvet M. Awakening properties of modafinil without paradoxical sleep rebound: A comparative study with amphetamine in the rat. Neurosci Lett 189 (1995) 43-46
21. Deroche-Gamonet V., Darnaudery M., Bruins-Slot L., Piat F., Le Moal M., and Piazza P.V. Study of the addictive potential of modafinil in naive and cocaine experienced rats. Psychopharmacology (Berl) 161 (2002) 387-395
22. Baptista T., ElFakih Y., Uzcátegui E., Sandia I., Tálamo E., Araujo de Baptista E., and Beaulieu S. Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs 22 (2008) 477-495
23. First M.B., Spitzer R., Gibbon M., and Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders. (Patient Edition, SCID-I/P, Version 2.0) (1995), New York State Psychiatric Institute, New York
24. Fairburn C.G., and Cooper Z. The eating disorder examination. In: Fairburn C.G., and Wilson G.T. (Eds). Binge Eating: Nature, Assessment and Treatment. 12th ed. (1993), Guilford Press, New York 317-360
25. Simpson G.M., and Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212 (1970) 11-19
26. Barnes T.R. A rating scale for drug induced akathisia. Br J Psychiatry 154 (1989) 672-676
27. Guy W. Abnormal involuntary movements. In: Guy W. (Ed). ECDUE Assessment Manual for Psychopharmacology (1976), National Institute of Mental Health, Rockville, MD
28. White M.A., Whisenhunt B.L., Williamson D.A., Greenway F.L., and Netemeyer R.G. Development and validation of the food-craving inventory. Obes Res 10 (2002) 107-114
29. Johns M.W. A new method for measuring daytime sleepiness: The Epworth sleepiness scale. Sleep 14 (1991) 540-545
30. Jarvis B.G. MediaLab Research Software. [computer program] (2006), Empirisoft, New York
31. University of Minnesota, Nutrition Coordinating Center. Nutrition Data System for Research (NDS-R) (1998), University of Minnesota, Division of Epidemiology and Community Health, School of Public Health, Minneapolis
32. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. (1988), Lawrence Erlbaum, Hillsdale, NJ
33. Cohen J. Eta-squared and partial eta-squared in fixed factor ANOVA designs. Educ Psychol Meas 33 (1973) 107-112
34. Henderson D.C., Louie P.M., Koul P., Namey L., Daley T.B., and Nguyen D.D. Modafinil-associated weight loss in a clozapine-treated schizoaffective disorder patient. Ann Clin Psychiatry 17 (2005) 95-97
35. Makris A.P., Rush C.R., Frederich R.C., and Kelly T.H. Wake-promoting agents with different mechanisms of action: Comparison of effects of modafinil and amphetamine on food intake and cardiovascular activity. Appetite 42 (2004) 185-195
36. Navarro V.J., and Senior J.R. Drug-related hepatotoxicity. N Engl J Med 354 (2006) 731-739
37. Hunter M.D., Ganesan V., Wilkinson I.D., and Spence S.A. Impact of modafinil on prefrontal executive function in schizophrenia. Am J Psychiatry 163 (2006) 2184-2186
38. Turner D.C., Clark L., Pomarol-Clotet E., McKenna P., Robbins T.W., and Sahakian B.J. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 29 (2004) 1363-1373
39. Rosenthal M.H., and Bryant S.L. Benefits of adjunct modafinil in an open-label, pilot study in patients with schizophrenia. Clin Neuropharmacol 27 (2004) 38-43
40. Sevy S., Rosenthal M.H., Alvir J., Meyer S., Visweswaraiah H., Gunduz-Bruce H., and Schooler N.R. Double-blind, placebo controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. J Clin Psychiatry 66 (2005) 839-843
41. Vorspan F., Warot D., Consoli A., Cohen D., and Mazet P. Mania in a boy treated with modafinil for narcolepsy. Am J Psychiatry 162 (2005) 813-814
42. Wolf J., Fiedler U., Anghelescu I., and Schwertfeger N. Manic switch in a patient with treatment-resistant bipolar depression treated with modafinil. J Clin Psychiatry 67 (2006) 1817
43. Frye M.A., Grunze H., Suppes T., McElroy S.L., Keck Jr. P.E., Walden J., et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry 164 (2007) 1242-1249
44. Wong Y.N., Simcoe D., Hartman L.N., Laughton W.B., King S.P., McCormick G.C., et al. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol 39 (1999) 30-40
45. Randall D.C., Shneerson J.M., Plaha K.K., and File S.E. Modafinil affects mood, but not cognitive function, in healthy young volunteers. Hum Psychopharmacol 18 (2003) 163-173
46. Baptista T., Kin N.M., Beaulieu S., and de Baptista E.A. Obesity and related metabolic abnormalities during antipsychotic drug administration: Mechanisms, management and research perspectives. Pharmacopsychiatry 35 (2002) 205-219
47. Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain: A literature analysis. Drug Saf 29 (2006) 303-319
48. Seeman M.V. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry 161 (2004) 1324-1333
49. Basson B.R., Kinon B.J., Taylor C.C., Szymanski K.A., Gilmore J.A., and Tollefson G.D. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 62 (2001) 231-238
50. Ascher-Svanum H., Stensland M., Zhao Z., and Kinon B.J. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry 5 (2005) 3